Arterial hypertension is the most prevalent modifiable risk factor associated with cardiovascular morbidity and mortality. Although antihypertensive drugs are widely available, in many patients blood pressure control to guideline-recommended target values is not achieved. Several device-based approaches have been introduced to lower blood pressure; most of these strategies aim to modulate autonomic nervous system activity. Clinical trials have moved from including patients with resistant hypertension receiving intensive pharmacological treatment to including patients with mild-to-moderate hypertension in the presence or absence of antihypertensive medications. Renal sympathetic denervation is the most extensively investigated device-based therapy for hypertension, and randomized, sham-controlled trials have provided proof-of-principle data for its blood pressure-lowering efficacy. Unilateral electrical baroreflex activation, endovascular baroreflex amplification and pacemaker-mediated cardiac neuromodulation therapy have yielded promising results in observational trials, which need to be confirmed in larger, adequately powered, sham-controlled trials. Until further evidence becomes available, device-based therapy for hypertension should not be considered for routine treatment. However, when considering a device-based treatment for hypertension, the underlying pathophysiology in each patient has to be taken into consideration, and the procedural risks weighed against the cardiovascular risk attributable to the elevated blood pressure. This Review summarizes the pathophysiological rationale and the latest clinical evidence for device-based therapies for hypertension.
The second generation of placebo-controlled trials of renal sympathetic denervation has provided proof of principle for the blood pressure-lowering efficacy of radiofrequency-based and ultrasound-based renal denervation in patients with or without concomitant pharmacological therapy.
Electrical baroreflex activation, endovascular baroreflex amplification and pacemaker-mediated cardiac neuromodulation therapy have yielded promising results in observational studies, which have to be confirmed in adequately powered, placebo-controlled trials.
The use of device-based therapies for hypertension should at present be restricted to clinical study activities in specialized centres.
When considering a device-based treatment for hypertension, the underlying pathophysiology has to be taken into consideration, and the procedural risks weighed against the cardiovascular risk attributable to the elevated blood pressure for each patient.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Clinical Hypertension Open Access 15 April 2022
Current Hypertension Reports Open Access 06 April 2022
Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation
Scientific Reports Open Access 26 January 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Forouzanfar, M. H. et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 317, 165–182 (2017).
Forouzanfar, M. H. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1659–1724 (2016).
Ettehad, D. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387, 957–967 (2016).
Williams, B. et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021–3104 (2018).
Whelton, P. K. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71, e13–e115 (2018).
Beaney, T. et al. May measurement month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob. Health 6, e736–e743 (2018).
Azizi, M., Rossignol, P. & Hulot, J.-S. Emerging drug classes and their potential use in hypertension. Hypertension 74, 1075–1083 (2019).
McMurray, J. J. V. et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).
Solomon, S. D. et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609–1620 (2019).
Velazquez, E. J. et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N. Engl. J. Med. 380, 539–548 (2019).
DiBona, G. F. Sympathetic nervous system and hypertension. Hypertension 61, 556–560 (2013).
Parati, G. & Esler, M. D. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur. Heart J. 33, 1058–1066 (2012).
DiBona, G. F. & Kopp, U. C. Neural control of renal function. Physiol. Rev. 77, 75–197 (1997).
DiBona, G. F. Neural control of the kidney: past, present, and future. Hypertension 41, 621–624 (2003).
Dibona, G. F. in Reviews of Physiology, Biochemistry and Pharmacology Vol. 94 75–181 (Springer, 1982).
DiBona, G. F. & Esler, M. Translational medicine: the antihypertensive effect of renal denervation. AJP Regul. Integr. Comp. Physiol. 298, R245–R253 (2010).
Smithwick, R. H. Surgical treatment of hypertension: the effect of radical (lumbodorsal) splanchnicectomy on the hypertensive state of one hundred and fifty-six patients followed one to five years. Arch. Surg. 49, 180–193 (1944).
Smithwick, R. H. & Thompson, J. E. Splanchnicectomy for essential hypertension: results in 1,266 cases. JAMA 152, 1501–1504 (1953).
Dustan, H. P., Page, I. H. & Poutasse, E. F. Renal hypertension. N. Engl. J. Med. 261, 647–653 (1959).
Peet, M. M. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am. J. Surg. 75, 48–68 (1948).
Page, I. H. & Heuer, G. J. A surgical treatment of essential hypertension. J. Clin. Invest. 14, 22–26 (1935).
[No authors listed] Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202, 1028–1034 (1967).
Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E. & Esler, M. D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361, 932–934 (2009).
Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275–1281 (2009).
Mabin, T., Sapoval, M., Cabane, V., Stemmett, J. & Iyer, M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention 8, 57–61 (2012).
Fischell, T. A. et al. Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine system: first-in-human experience. JACC Cardiovasc. Interv. 9, 589–598 (2016).
Mahfoud, F. et al. Alcohol-mediated renal denervation using the Peregrine System Infusion Catheter for treatment of hypertension. JACC Cardiovasc. Interv. 13, 471–484 (2020).
Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
Poulter, N. R., Prabhakaran, D. & Caulfield, M. Hypertension. Lancet 386, 801–812 (2015).
Messerli, F. H., Williams, B. & Ritz, E. Essential hypertension. Lancet 370, 591–603 (2007).
Mahfoud, F. et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 128, 132–140 (2013).
Vogel, B. et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin. Res. Cardiol. 103, 117–124 (2014).
Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).
Kandzari, D. E. et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur. Heart J. 36, 219–227 (2015).
Mahfoud, F. et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur. Heart J. 38, 3272–3281 (2017).
Azizi, M. et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385, 1957–1965 (2015).
Azizi, M. et al. Adherence to antihypertensive treatment and the blood pressure–lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial. Circulation 134, 847–857 (2016).
Fadl Elmula, F. E. M. et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press. 26, 195–203 (2017).
Pappaccogli, M. et al. Effectiveness of renal denervation in resistant hypertension: a meta-analysis of 11 controlled studies. High Blood Press. Cardiovasc. Prev. 25, 167–176 (2018).
Sardar, P. et al. Sham-controlled randomized trials of catheter-based renal denervation in patients with hypertension. J. Am. Coll. Cardiol. 73, 1633–1642 (2019).
Mahfoud, F. et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur. Heart J. 36, 2219–2227 (2015).
Lobo, M. D. et al. Joint UK societies’ 2019 consensus statement on renal denervation. Heart 105, 1456–1463 (2019).
Kiuchi, M. G. et al. Renal denervation update from the International Sympathetic Nervous System Summit. J. Am. Coll. Cardiol. 73, 3006–3017 (2019).
Townsend, R. R. et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390, 2160–2170 (2017).
Kandzari, D. E. et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391, 2346–2355 (2018).
Azizi, M. et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 6736, 1–11 (2018).
Kandzari, D. E. et al. The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am. Heart J. 171, 82–91 (2015).
Sakakura, K. et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J. Am. Coll. Cardiol. 64, 635–643 (2014).
Mahfoud, F. et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J. Am. Coll. Cardiol. 66, 1766–1775 (2015).
Tzafriri, A. R. et al. Innervation patterns may limit response to endovascular renal denervation. J. Am. Coll. Cardiol. 64, 1079–1087 (2014).
Böhm, M. et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. Eur. Heart J. 40, 743–751 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02439749 (2019).
Mauri, L. et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs. Am. Heart J. 195, 115–129 (2018).
Azizi, M. et al. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. Circulation 139, 2542–2553 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02918305 (2020)
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03614260 (2020).
Schmieder, R. E. et al. European Society of Hypertension position paper on renal denervation 2018. J. Hypertens. 36, 2042–2048 (2018).
Fischell, T. A., Fischell, D. R., Ghazarossian, V. E., Vega, F. & Ebner, A. Next generation renal denervation: chemical “perivascular” renal denervation with alcohol using a novel drug infusion catheter. Cardiovasc. Revasc. Med. 16, 221–227 (2015).
Fischell, T. A. et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. EuroIntervention 9, 140–147 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02910414 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03503773 (2019).
Cai, X. et al. Noninvasive stereotactic radiotherapy for renal denervation in a swine model. J. Am. Coll. Cardiol. 74, 1697–1709 (2019).
Mahfoud, F., Edelman, E. & Bhatt, N. Stereotactic radiotherapy for renal denervation. J. Am. Coll. Cardiol. 74, 1710–1713 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01534299 (2019).
Mahfoud, F. et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur. Heart J. 40, 1211–1213 (2019).
Salam, A. et al. Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean. J. Hypertens. 37, 16–23 (2019).
Kordalis, A., Tsiachris, D., Pietri, P., Tsioufis, C. & Stefanadis, C. Regression of organ damage following renal denervation in resistant hypertension. J. Hypertens. 36, 1614–1621 (2018).
Messerli, F. H., Bangalore, S. & Schmieder, R. E. Wilder’s principle: pre-treatment value determines post-treatment response. Eur. Heart J. 36, 576–579 (2015).
Moore, M. N. et al. Regression to the mean of repeated ambulatory blood pressure monitoring in five studies. J. Hypertens. 37, 24–29 (2019).
Mahfoud, F. et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur. Heart J. 38, 93–100 (2017).
Gosse, P. et al. Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation: the DENERHTN study (renal denervation for hypertension). Hypertension 69, 494–500 (2017).
Okon, T. et al. Invasive aortic pulse wave velocity as a marker for arterial stiffness predicts outcome of renal sympathetic denervation. EuroIntervention 12, e684–e692 (2016).
Courand, P. et al. Abdominal aortic calcifications influences the systemic and renal hemodynamic response to renal denervation in the DENERHTN (renal denervation for hypertension) trial. J. Am. Heart Assoc. 6, 1–15 (2017).
Gal, P. et al. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J. Hum. Hypertens. 29, 292–295 (2015).
de Jong, M. R. et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension 68, 707–714 (2016).
Tsioufis, C. et al. ConfidenHTTM system for diagnostic mapping of renal nerves. Curr. Hypertens. Rep. 20, 49 (2018).
Fengler, K. et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation 139, 590–600 (2019).
Kline, R. L. & Mercer, P. F. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am. J. Physiol. Integr. Comp. Physiol. 238, R353–R358 (1980).
Booth, L. C. et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 65, 393–400 (2015).
Mulder, J. et al. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am. J. Physiol. Integr. Comp. Physiol. 304, R675–R682 (2013).
Krum, H. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383, 622–629 (2014).
Singh, R. R. et al. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension 73, 718–727 (2019).
van Kleef, M. E. A. M., Bates, M. C. & Spiering, W. Endovascular baroreflex amplification for resistant hypertension. Curr. Hypertens. Rep. 20, 46 (2018).
Heusser, K. et al. Acute response to unilateral unipolar electrical carotid sinus stimulation in patients with resistant arterial hypertension. Hypertension 67, 585–591 (2016).
Rothfeld, E. L. et al. The effect of carotid sinus nerve stimulation on cardiovascular dynamics in man. Angiology 20, 213–218 (1969).
Lohmeier, T. E. et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am. J. Physiol. Heart Circ. Physiol. 299, H402–H409 (2010).
Lohmeier, T. E., Irwin, E. D., Rossing, M. A., Serdar, D. J. & Kieval, R. S. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 43, 306–311 (2004).
Scheffers, I. J. M. et al. Novel baroreflex activation therapy in resistant hypertension. J. Am. Coll. Cardiol. 56, 1254–1258 (2010).
Tordoir, J. H. M. et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur. J. Vasc. Endovasc. Surg. 33, 414–421 (2007).
Heusser, K. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55, 619–626 (2010).
Wustmann, K. et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 54, 530–536 (2009).
Bisognano, J. D. et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J. Am. Coll. Cardiol. 58, 765–773 (2011).
de Leeuw, P. W. et al. Sustained reduction of blood pressure with baroreceptor activation therapy. Hypertension 69, 836–843 (2017).
de Leeuw, P. W. et al. Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 65, 187–192 (2015).
Gassler, J. P. & Bisognano, J. D. Baroreflex activation therapy in hypertension. J. Hum. Hypertens. 28, 469–474 (2014).
Hoppe, U. C. et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J. Am. Soc. Hypertens. 6, 270–276 (2012).
Lohmeier, T. E. & Hall, J. E. Device-based neuromodulation for resistant hypertension therapy. Circ. Res. 124, 1071–1093 (2019).
Wachter, R. et al. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J. Am. Soc. Hypertens. 11, 81–91 (2017).
Wallbach, M. et al. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system. Clin. Res. Cardiol. 109, 513–522 (2019).
Wallbach, M. et al. Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension. J. Hypertens. 36, 1762–1769 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01679132 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02364310 (2019).
Gordin, D. et al. The effects of baroreflex activation therapy on blood pressure and sympathetic function in patients with refractory hypertension: the rationale and design of the Nordic BAT study. Blood Press. 26, 294–302 (2017).
Cowley, A. W., Liard, J. F. & Guyton, A. C. Role of the baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ. Res. 32, 564–576 (1973).
Mendelowitz, D. & Scher, A. M. Pulsatile sinus pressure changes evoke sustained baroreflex responses in awake dogs. Am. J. Physiol. Circ. Physiol 255, H673–H678 (1988).
Dorward, P. K., Andresen, M. C., Burke, S. L., Oliver, J. R. & Korner, P. I. Rapid resetting of the aortic baroreceptors in the rabbit and its implications for short-term and longer term reflex control. Circ. Res. 50, 428–439 (1982).
Peter, D. A. et al. Fluid structure interaction with contact surface methodology for evaluation of endovascular carotid implants for drug-resistant hypertension treatment. J. Biomech. Eng. 134, 041001 (2012).
Spiering, W. et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 390, 2655–2661 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01831895 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02827032 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03179800 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02804087 (2020).
Al-Ameri, H. et al. Complication rate of diagnostic carotid angiography performed by interventional cardiologists. Catheter. Cardiovasc. Interv. 73, 661–665 (2009).
Trzebski, A., Tafil, M., Zoltowski, M. & Przybylski, J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc. Res. 16, 163–172 (1982).
Sin΄ski, M. et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens. Res. 35, 487–491 (2012).
Fletcher, E. C. et al. Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J. Appl. Physiol. 72, 1978–1984 (1992).
Heusser, K. et al. Cardiovascular regulation during apnea in elite divers. Hypertension 53, 719–724 (2009).
Abdala, A. P. et al. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J. Physiol. 590, 4269–4277 (2012).
Del Rio, R., Marcus, N. J. & Schultz, H. D. Carotid chemoreceptor ablation improves survival in heart failure. J. Am. Coll. Cardiol. 62, 2422–2430 (2013).
Narkiewicz, K. et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci. 1, 313–324 (2016).
Schlaich, M. et al. Transvenous carotid body ablation for resistant hypertension: main results of a multicentre safety and proof-of-principle cohort study [abstract 1416]. Eur. Heart J. 39, 267 (2018).
Neuzil, P. et al. Pacemaker-mediated programmable hypertension control therapy. J. Am. Heart Assoc. 6, 1–14 (2017).
Liebold, A., Rödig, G., Merk, J. & Birnbaum, D. E. Short atrioventricular delay dual-chamber pacing early after coronary artery bypass grafting in patients with poor left ventricular function. J. Cardiothorac. Vasc. Anesth. 12, 284–287 (1998).
Kuck, K.-H. et al. Safety and efficacy of BackBeat cardiac neuromodulation therapy (CNTTM) in patients with hypertension: final results of a double-blind randomized trial. Presented at the TCT Congress (2019).
Reynolds, D. et al. A leadless intracardiac transcatheter pacing system. N. Engl. J. Med. 374, 533–541 (2016).
Zhang, X.-H. et al. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J. Cardiovasc. Electrophysiol. 19, 136–141 (2008).
The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288, 3115–3123 (2002).
Kapil, V., Sobotka, P. A., Lobo, M. D. & Schmieder, R. E. Central arteriovenous anastomosis to treat resistant hypertension. Curr. Opin. Nephrol. Hypertens. 27, 8–15 (2018).
Scholz, S. S. et al. Effects of arteriovenous fistula on blood pressure in patients with end-stage renal disease: a systematic meta-analysis. J. Am. Heart Assoc. 8, 1–12 (2019).
Iwashima, Y. et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am. J. Kidney Dis. 40, 974–982 (2002).
Jordan, J. Device-based approaches for the treatment of arterial hypertension. Curr. Hypertens. Rep. 19, 59 (2017).
Foran, J. P. et al. The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. Catheter. Cardiovasc. Interv. 85, 880–886 (2015).
Faul, J. et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J. Vasc. Surg. 59, 1078–1083 (2014).
Brouwers, S. et al. A prospective non-randomized open label multi-center study to evaluate the effect of an iliofemoral arteriovenous fistula on blood pressure in patients with therapy-resistant hypertension [abstract]. Eur. Heart J. 34 (Suppl. 1), 3616–655 (2013).
Lobo, M. D. et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 385, 1634–1641 (2015).
Lobo, M. D. et al. Central iliac arteriovenous anastomosis for uncontrolled hypertension. Hypertension 70, 1099–1105 (2017).
Ott, C. et al. Effect of arteriovenous anastomosis on blood pressure reduction in patients with isolated systolic hypertension compared with combined hypertension. J. Am. Heart Assoc. 5, e004234 (2016).
Ewen, S., Lauder, L., Böhm, M. & Mahfoud, F. Real-time left ventricular pressure–volume loops during percutaneous central arteriovenous anastomosis. Eur. Heart J. 39, 2330–2331 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02895386 (2019).
Roy-Chaudhury, P., Sukhatme, V. P. & Cheung, A. K. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J. Am. Soc. Nephrol. 17, 1112–1127 (2006).
Lauder, L., Ewen, S., Böhm, M., Scheller, B. & Mahfoud, F. Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis. Clin. Res. Cardiol. 108, 574–576 (2019).
Desch, S. et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 65, 1202–1208 (2015).
Mathiassen, O. N. et al. Renal denervation in treatment-resistant essential hypertension. A randomized, sham-controlled, double-blinded 24-h blood pressure-based trial. J. Hypertens. 34, 1639–1647 (2016).
Fadl Elmula, F. E. M. et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 63, 991–999 (2014).
Rosa, J. et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 65, 407–413 (2015).
Kario, K. et al. SYMPLICITY HTN-Japan: first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ. J. 79, 1222–1229 (2015).
Oliveras, A. et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study – A randomized controlled trial. J. Hypertens. 34, 1863–1871 (2016).
de Jager, R. L. et al. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension 69, 678–684 (2017).
Jacobs, L. et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 26, 321–331 (2017).
Warchol-Celinska, E. et al. Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of-concept phase II trial. Hypertension 72, 381–390 (2018).
Kyvelou, S. M. et al. Renal denervation: the Irish experience. Hellenic J. Cardiol. 54, 486–487 (2013).
Worthley, S. G. et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur. Heart J. 34, 2132–2140 (2013).
Kaiser, L. et al. Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. EuroIntervention 10, 157–165 (2014).
Dores, H. et al. Renal denervation in patients with resistant hypertension: six-month results. Rev. Port. Cardiol. 33, 197–204 (2014).
Verheye, S. et al. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study. EuroIntervention 10, 1221–1229 (2015).
Sievert, H. et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention 10, 1213–1220 (2015).
Whitbourn, R., Harding, S. A. & Walton, A. Symplicity multi-electrode radiofrequency renal denervation system feasibility study. EuroIntervention 11, 104–109 (2015).
Sharp, A. S. P. et al. Renal artery sympathetic denervation: observations from the UK experience. Clin. Res. Cardiol. 105, 544–552 (2016).
Zweiker, D. et al. Effects of renal denervation cocumented in the Austrian national multicentre renal denervation tegistry. PLoS One 11, e0161250 (2016).
Worthley, S. G. et al. Safety and performance of the second generation EnligHTNTM Renal Denervation System in patients with drug-resistant, uncontrolled hypertension. Atherosclerosis 262, 94–100 (2017).
Aripov, M. et al. Individualised renal artery denervation improves blood pressure control in Kazakhstani patients with resistant hypertension. Kardiol. Pol. 75, 101–107 (2017).
Völz, S. et al. Renal sympathetic denervation in Sweden. J. Hypertens. 36, 151–158 (2018).
Daemen, J. et al. Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension. J. Hypertens. 37, 1906–1912 (2019).
M.A. reports grants from the French Federation of Cardiology, the French Ministry of Health, Idorsia, Novartis and Quantum Genomics; grants and non-financial support from ReCor Medical; and speaker honoraria from CVRx and Novartis. A.J.K. reports institutional funding to Columbia University and/or Cardiovascular Research Foundation from Abbott Vascular, Abiomed, Boston Scientific, CSI, Medtronic, Philips and ReCor Medical. M.B. receives support from Abbott, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Deutsche Forschungsgemeinschaft (DFG, TTR 219, S-01, M-03, M-05), Medtronic, Novartis, ReCor Medical, Servier and Vifor. F.M. receives support from Deutsche Hochdruckliga (DHL), Deutsche Gesellschaft für Kardiologie (DGK) and DFG (SFB TRR219) and has received scientific support and speaker honoraria from Medtronic and ReCor Medical. L.L. declares no competing interests.
Peer review information
Nature Reviews Cardiology thanks S. Oparil, V. Papademetriou and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lauder, L., Azizi, M., Kirtane, A.J. et al. Device-based therapies for arterial hypertension. Nat Rev Cardiol 17, 614–628 (2020). https://doi.org/10.1038/s41569-020-0364-1
This article is cited by
Clinical Hypertension (2022)
Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation
Scientific Reports (2022)
Hypertension Research (2022)
Current Hypertension Reports (2022)
A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model
Clinical Research in Cardiology (2022)